Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Cancer|June 23, 2022
Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignanciesAntoine Hollebecque, Stefania Salvagni, Ruth Plummer, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 28, 2012
EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activationSantiago Montes-Moreno, Lina Odqvist, Julio A Diaz-Perez, et al.
Leukemia & Lymphoma|September 20, 2022
Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM)Ana Villalba, Ana Pilar Gonzalez-Rodriguez, Javier Arzuaga-Mendez, et al.
Blood|December 4, 2023
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myelomaCamila Guerrero, Noemi Puig, María-Teresa Cedena, et al.
British Journal of Haematology|May 20, 2020
Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective studySocorro Maria Rodriguez-Pinilla, Eva Domingo-Domenech, Fina Climent, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2022
A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple MyelomaCamila Guerrero, Noemi Puig, Maria-Teresa Cedena, et al.
Blood Cancer Discovery|April 15, 2025
Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple MyelomaCamila Guerrero, Maria-Jose Larrayoz, Irache Erdozain, et al.
British Journal of Haematology|January 21, 2017
Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β<sub>2</sub> -microglobulin yields a more accurate GELTAMO-IPICarlos Montalbán, Antonio Díaz-López, Ivan Dlouhy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2024
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd MaintenanceMaría-Victoria Mateos, Joaquin Martínez-López, Paula Rodriguez Otero, et al.
Hemasphere|October 13, 2025
Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN-HARMONY Alliance platformAdrian Mosquera Orgueira, Marta Sonia Gonzalez Perez, Mattia D'Agostino, et al.
Pageof 5